Latest / Community Health Media
Special CHM Conversation: Second-Line ER+/HER2- mBC with Drs. Seth Wander & Paolo Tarantino
How is the rapidly changing treatment landscape reshaping second-line ER-positive, HER2-negative metastatic breast cancer care?
In this Special CHM Conversation, Dr. Seth Wander and Dr. Paolo Tarantino discuss the growing number of endocrine therapy options and how clinicians can navigate increasingly complex treatment decisions.
They explore what the newly approved combination of imlunestrant plus abemaciclib means for patients with ESR1 mutations, how ctDNA and molecular profiling guide treatment selection, and why sequencing next-generation endocrine therapies remains an open question as…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.